Apixaban Dosing in Atrial Fibrillation with Renal Impairment

Standard Dosing and Dose Reduction Criteria

The American College of Cardiology recommends a standard dose of apixaban of 5 mg twice daily for nonvalvular atrial fibrillation, unless the patient meets dose reduction criteria, which includes having at least two of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1, 2
A creatinine clearance of 30 mL/min alone does not warrant dose reduction unless other criteria are met, as stated by the American College of Cardiology 1, 2
The standard dose of apixaban for patients with creatinine clearance of 30 mL/min is 5 mg twice daily, according to the American College of Cardiology 1

The American College of Cardiology, American Heart Association, American College of Chest Physicians, and Heart Rhythm Society guideline recommends apixaban 5 mg twice daily for patients with creatinine clearance 31-50 mL/min, with a moderate level of evidence 1
Patients with creatinine clearance of 30 mL/min fall into the 15-30 mL/min category in the guidelines, which still supports the use of standard or reduced dosing based on other criteria, not solely on renal function, as stated by the American College of Cardiology 1

For patients undergoing procedures with a creatinine clearance >25 mL/min, the American College of Cardiology recommends discontinuing apixaban 1 day before low bleeding risk procedures and 2 days before high bleeding risk procedures 1
For patients with creatinine clearance lower than 25 mL/min, the American College of Cardiology suggests considering holding apixaban for an additional 1-3 days, especially for high bleeding risk procedures, based on expert opinion 1

Apixaban has lower renal clearance (approximately 27%) compared to other NOACs, making it more suitable for patients with renal impairment, according to Praxis Medical Insights 3
Inappropriate dose reduction based solely on creatinine clearance of 30 mL/min without considering other factors (age, weight) may lead to suboptimal stroke prevention, as warned by Praxis Medical Insights 2